The scientific basis for the use of the linear no-threshold (LNT) model at low doses and dose rates in radiological protection.


Journal

Journal of radiological protection : official journal of the Society for Radiological Protection
ISSN: 1361-6498
Titre abrégé: J Radiol Prot
Pays: England
ID NLM: 8809257

Informations de publication

Date de publication:
29 06 2023
Historique:
received: 07 04 2023
accepted: 20 06 2023
medline: 30 6 2023
pubmed: 21 6 2023
entrez: 20 6 2023
Statut: epublish

Résumé

The linear no-threshold (LNT) model was introduced into the radiological protection system about 60 years ago, but this model and its use in radiation protection are still debated today. This article presents an overview of results on effects of exposure to low linear-energy-transfer radiation in radiobiology and epidemiology accumulated over the last decade and discusses their impact on the use of the LNT model in the assessment of radiation-related cancer risks at low doses. The knowledge acquired over the past 10 years, both in radiobiology and epidemiology, has reinforced scientific knowledge about cancer risks at low doses. In radiobiology, although certain mechanisms do not support linearity, the early stages of carcinogenesis comprised of mutational events, which are assumed to play a key role in carcinogenesis, show linear responses to doses from as low as 10 mGy. The impact of non-mutational mechanisms on the risk of radiation-related cancer at low doses is currently difficult to assess. In epidemiology, the results show excess cancer risks at dose levels of 100 mGy or less. While some recent results indicate non-linear dose relationships for some cancers, overall, the LNT model does not substantially overestimate the risks at low doses. Recent results, in radiobiology or in epidemiology, suggest that a dose threshold, if any, could not be greater than a few tens of mGy. The scientific knowledge currently available does not contradict the use of the LNT model for the assessment of radiation-related cancer risks within the radiological protection system, and no other dose-risk relationship seems more appropriate for radiological protection purposes.

Identifiants

pubmed: 37339605
doi: 10.1088/1361-6498/acdfd7
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Commentaires et corrections

Type : CommentIn

Informations de copyright

Creative Commons Attribution license.

Auteurs

Dominique Laurier (D)

Institute for Radiological Protection and Nuclear Safety (IRSN), Fontenay-aux-Roses, France.

Yann Billarand (Y)

Institute for Radiological Protection and Nuclear Safety (IRSN), Fontenay-aux-Roses, France.

Dmitry Klokov (D)

Institute for Radiological Protection and Nuclear Safety (IRSN), Fontenay-aux-Roses, France.

Klervi Leuraud (K)

Institute for Radiological Protection and Nuclear Safety (IRSN), Fontenay-aux-Roses, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH